STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Nov. 30, 2021

Equity [Abstract]

Schedule of Stock-based Compensation Expense

Stock-based compensation expense is included in the following captions of the condensed consolidated statements of comprehensive loss (in thousands):

	Three Months Ended					Nine Months Ended
	November 30,					November 30,
	2021			2020		2021		2020
Cost of revenues	$	66		$	172	$	82	$	480
Research and development		726			717		2,240		1,940
Selling and marketing		856			611		2,146		1,602
General and administrative		1,655			1,146		4,061		3,469
Restructuring		—			—		—		875
Other non-operating expense		(151	)		—		32		—
	$	3,152		$	2,646	$	8,561	$	8,366

Summary of Stock Option Activity

Changes in our outstanding stock options during the nine months ended November 30, 2021 were as follows (options in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted average remaining contractual life (years)		Aggregate intrinsic value
Outstanding at February 28, 2021		778		$	16.01		6.0
Granted		—			—
Exercised		(33	)		7.53
Forfeited or expired		(76	)		16.49
Outstanding at November 30, 2021		669		$	16.37		5.6	$	39
Exercisable at November 30, 2021		543		$	16.33		5.1	$	20

Summary of Restricted Stock Shares (RSU's), and Performance Stock Units (PSU's) Activity

Changes in our outstanding restricted stock shares, performance stock units (“PSUs”) and restricted stock units (“RSUs”) during the nine months ended November 30, 2021 were as follows (restricted shares, PSUs and RSUs in thousands):

	Number of Restricted Shares, PSUs and RSUs			Weighted Average Grant Date Fair Value		Shares Retained to Cover Statutory Minimum Withholding Taxes
Outstanding at February 28, 2021		3,053		$	10.61
Granted		1,296			12.20
Vested		(918	)		11.81		336
Forfeited		(485	)		10.78
Outstanding at November 30, 2021		2,946		$	10.89